Prof. Hezi Levy joins BioHarvest Sciences (NASDAQ: BHST) Board as Tsur exits

Rhea-AI Filing Summary

BioHarvest Sciences Inc. filed a Form 6-K to report a Board transition. Long-serving director David Tsur is stepping down after more than four years of service, during which he supported the company’s strategic development, governance, and growth initiatives.

The company has appointed Prof. Hezi Levy to its Board of Directors, effective immediately. Prof. Levy brings decades of leadership experience across Israel’s healthcare system, including roles as Director General of the Israeli Ministry of Health, Head of the Israel Defense Forces Medical Corps, and General Manager of Barzilai Medical Center.

Chairman Zaki Rakib highlighted that Prof. Levy’s medical and executive background is expected to strengthen governance as BioHarvest scales its direct-to-consumer products and advances its biotechnology CDMO platform based on its Botanical Synthesis technology.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated March 5, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: March 5, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy

Vancouver, British Columbia and Rehovot, Israel – March 5, 2026 – BioHarvest Sciences Inc. (NASDAQ: BHST) (“BioHarvest” or the “Company”), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.

Mr. Tsur has served on BioHarvest’s Board since 2021 and has contributed meaningfully to the Company’s strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.

Zaki Rakib, Chairman of BioHarvest, commented, “On behalf of the Board and management team, I would like to sincerely thank David for his leadership, experience and dedication over the past four years. His wisdom and guidance have supported BioHarvest’s growth and strategic evolution. We are grateful for his contributions and wish him continued success.”

Prof. Hezi Levy joins the Board with decades of leadership experience across Israel’s healthcare system, recognized globally as one of the world’s most advanced. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy during a period of exceptional challenge.

 

Figure 1. Professor Hezi Levy

Prof. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel’s major hospitals and complex healthcare operations.

Chairman Zaki Rakib added, “We are honored to welcome Prof. Levy to the BioHarvest Board. His deep medical expertise, executive leadership and experience managing large healthcare systems will add significant strength to our governance as we execute our scaling of our direct-to-consumer products business while advancing our high-value biotechnology CDMO platform.”

About BioHarvest

BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is not certain, may take significant time, and is subject to risks and uncertainties beyond company control such as consumer preferences, competition landscape, government approvals required for sale or import, acceptance of benefit claims, and marketing budgets of the company and its competitors. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Contacts:

BioHarvest Corporate Contact:

Dave Ryan, VP Investor Relations

+1 (604) 622-1186

info@bioharvest.com

FAQ

What Board changes did BioHarvest Sciences (BHST) announce in this Form 6-K?

BioHarvest Sciences announced that director David Tsur will step down from its Board after more than four years of service. The company simultaneously appointed Prof. Hezi Levy to the Board of Directors, with the appointment stated as being effective immediately in the disclosure.

Who is Prof. Hezi Levy, the new Board member at BioHarvest Sciences (BHST)?

Prof. Hezi Levy is a physician and senior healthcare leader who previously served as Director General of the Israeli Ministry of Health, including during COVID-19. He also led the Israel Defense Forces Medical Corps and managed Barzilai Medical Center, one of Israel’s major hospitals.

Why did BioHarvest Sciences (BHST) highlight Prof. Levy’s background in this announcement?

BioHarvest emphasized Prof. Levy’s deep medical expertise, executive leadership, and experience managing large healthcare systems. Chairman Zaki Rakib stated this background will strengthen governance as the company scales its direct-to-consumer products business and advances its high-value biotechnology CDMO platform based on Botanical Synthesis.

How long did David Tsur serve on the BioHarvest Sciences (BHST) Board?

The company stated that David Tsur has served on the Board since 2021, contributing over four years. During this time he supported strategic development, governance, operational expansion, capital formation, product commercialization, and market positioning, according to comments from Chairman Zaki Rakib in the announcement.

What does BioHarvest Sciences (BHST) describe as its core business focus?

BioHarvest describes itself as a leader in Botanical Synthesis, using a patented technology platform to grow plant-based compounds without growing the full plant. It operates two main verticals: CDMO services for plant-based compounds and proprietary nutraceutical health and wellness products, including dietary supplements.

Does the BioHarvest Sciences (BHST) news release contain forward-looking statements?

Yes. The release notes that some information constitutes forward-looking statements, based on management’s current expectations and subject to risks and uncertainties. It cautions that actual results may differ materially, notes uncertainties around contracts and new product launches, and advises readers not to place undue reliance on such statements.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED MARCH 5, 2026 7.8 KB